BioNTech and Fosun Pharma, Samsung Biologics and Fujifilm's Avigan made our news this week. (Google)
As BioNTech makes inroads with Pfizer for their COVID-19 vaccine in the Western world, the German biotech has agreed to supply 100 million doses for its Chinese partner, Fosun Pharma. Samsung Biologics promoted John Rim to take over as CEO. Japan's drug reviewers were unsure whether Fujifilm's flu drug Avigan should be allowed to treat COVID-19. And more.
BioNTech struck a deal with its Chinese partner, Fosun Pharma, to supply 100 million doses of its COVID-19 vaccine, BNT162b2, in China in 2021. The vaccine is currently in a phase 2 bridging trial in China, and the results will be combined with those from the global phase 3 for its local regulatory submission.
Read more on